The DSRU welcomes the UK’s decision to have continued involvement in EU medicines regulation after Brexit. The UK Parliament voted last night for the UK to participate in the regulatory network operated by the European Medicines Agency (EMA) after it leaves the EU. The government confirmed that it would make an “appropriate financial contribution” in return for this level of participation.
The DSRU believes that the overall aim should be to ensure that citizens of the UK and the EU continue to gain access to the best and most innovative medicines. The DSRU will continue to support the MHRA and the EMA in their efforts to achieve this aim.